97152-40-4

Basic information

• Product Name: 2,2',3,3',4,4'-hexakis(benzyloxy)-1,1'-biphenyl-6,6'-dicarboxylic acid
• Synonyms: 2,2',3,3',4,4'-hexakis(benzyloxy)-1,1'-biphenyl-6,6'-dicarboxylic acid
• CAS NO: 97152-40-4
• Molecular Weight: 878.975
• Mol File: 97152-40-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2,2',3,3',4,4'-hexakis(benzyloxy)-1,1'-biphenyl-6,6'-dicarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2',3,3',4,4'-hexakis(benzyloxy)-1,1'-biphenyl-6,6'-dicarboxylic acid(97152-40-4)
• EPA Substance Registry System: 2,2',3,3',4,4'-hexakis(benzyloxy)-1,1'-biphenyl-6,6'-dicarboxylic acid(97152-40-4)

Safety Data

• Hazardous Substances Data: 97152-40-4(Hazardous Substances Data)

Upstream product

• 100-44-7 benzyl chloride 
• 915215-48-4 2,2'-dihydroxy-3,3,',4,4'-tetrakis(benzyloxy)-1,1'-biphenyl-6,6'-dicarboxylic acid 
• 476-66-4 ellagic acid 
• 103442-14-4 tetrabenzylellagic acid 
• 100-39-0 benzyl bromide 
• 154675-20-4 dibenzyl 2,2',3,3',4,4'-hexabenzyloxybiphenyl-6,6'-dicarboxylate 

Downstream Products

• 193535-28-3 2,2',3,3',4,4'-hexabenzyloxydiphenyl-6,6'-dicarboxylic acid chloride 
• 188855-50-7 (R)-4,5,6,4',5',6'-hexabenzyloxydiphenic acid 
• 188855-50-7 (S)-4,5,6,4',5',6'-hexabenzyloxydiphenic acid 
• 154675-07-7 (R)-4,5,6,4',5',6'-hexabenzyloxydiphenate dimethyl ester 
• 154675-07-7 (S)-4,5,6,4',5',6'-hexabenzyloxydiphenate dimethyl ester 
• 149020-60-0 (+/-)-4,4',5,5',6,6'-Hexakis-benzyloxy-2,2'-bis-brommethyl-biphenyl 
• 107420-43-9 (+/-)-2'.3'.4'.1''.2''.3''-Hexakis-(benzyloxy)-5-cyan-1.2.3.4-dibenz-cycloheptadien-(1.3)-on-⁽⁶⁾ 
• 107062-70-4 (+/-)-2'.3'.4'.1''.2''.3''-Hexakis-(benzyloxy)-5-cyan-1.2.3.4-dibenz-cycloheptadien-(1.3)-imin-⁽⁶⁾ 
• 107062-71-5 (+/-)-2'.3'.4'.1''.2''.3''-Hexakis--5-cyan-1.2.3.4-dibenz-cyclohepta-dien-(1.3)-ol-(6) 
• 154675-19-1 2,2',3,3'4,4'-hexakis(benzyloxy)-1,1'-biphenyl-6,6'-dimethanol dimethyl ether 

Relevant articles and documents

Synthetic studies toward c-glucosidic ellagitannins: A biomimetic total synthesis of 5-O-desgalloylepipunicacortein A

C-glucosidic ellagitannins constitute a subclass of bioactive polyphenolic natural products with strong antioxidant properties, as well as promising antitumoral and antiviral activities that are related to their capacity to interact with both functional and structural proteins. To date, most synthetic efforts toward ellagitannins have concerned glucopyranosic species. The development of a synthetic strategy to access C-glucosidic ellagitannins, whose characteristic structural feature includes an atropoisomeric hexahydroxydiphenoyl (HHDP) or a nonahydroxyterphenoyl (NHTP) unit that is linked to an open-chain glucose core by a C-aryl glucosidic bond, is described herein. The total synthesis of the biarylic HHDP-containing 5-O- desgalloylepipunicacortein A (1 β) was achieved by either using the natural ellagic acid bis-lactone as a precursor of the requested HHDP unit or by implementing an atroposelective intramolecular oxidative biarylic coupling to forge this HHDP unit. Both routes converged in the penultimate step of this synthesis to enable a biomimetic formation of the key C-aryl glucosidic bond in the title compound.

OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING -AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME

The present invention provides a chiral phase-transfer catalyst of the following formula (I): The compound (I) can be produced by reacting a 2,2'-dimethylene bromide-1,1'-biphenyl derivative, which can be produced through comparatively small number of steps, with an easily available secondary amine.

New hexahydroxybiphenyl derivatives as inhibitors of protein kinase C

We have previously shown that some ellagitannins are potent inhibitors of protein kinase C (PKC). On the basis of this finding, several series of hexahydroxybiphenyl derivatives of ellagic acid were synthesized as simple analogs of these ellagitannins and were evaluated for their inhibitory effect against PKC. Compounds 23 and 26 were found to be potent inhibitors of PKC, while hexakis(benzyloxy)biphenyl derivatives exhibited weak anti-PKC activity.